A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

NCT06219356 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: GLB-002

Sponsor

Hangzhou GluBio Pharmaceutical Co., Ltd.